Retatrutide's phase 2 heart-rate signal and how to think about it

This follows post #2 rather than contradicting it.

Discontinuation for adverse effects in phase 2 was not negligible at the higher doses. That figure belongs next to the efficacy figure whenever the efficacy figure is quoted.

The part I am sure of is shorter than the part I have written.

Duration is the other limitation. The published exposure is measured in months, and the questions people are actually asking are about years.

The strength of my opinion here exceeds the strength of my evidence.

Where I part company with post #8, and it is a narrow parting.

What we do not know about retatrutide, listed explicitly: long-term safety, real-world response rates, the dose response in diverse populations, whether the heart-rate signal persists or attenuates, durability of effect on withdrawal, efficacy in comorbidities beyond obesity.

The disagreement above is smaller than it looks once the terms are fixed.

Useful. I had the fact and not the reason, which turns out to be the important half.

The phase 2 obesity paper reported dose-dependent weight reduction of a magnitude that attracted attention. It also reported dose-dependent heart-rate increases. The heart-rate signal is the reason phase 3 exists rather than something assumed negligible based on phase 2.

That matches what I was told, which is not the same as knowing it.